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Abstract: Biological variation (BV) data have many appli-
cations in laboratory medicine. However, concern has 
been raised that some BV estimates in use today may be 
irrelevant or of unacceptable quality. A number of ini-
tiatives have been launched by the European Federation 
of Clinical Chemistry and Laboratory Medicine (EFLM) 
and other parties to deliver a more harmonized practice 
in the generation, reporting and application of BV data. 
Resulting from a necessary focus upon the veracity of his-
torical BV studies, critical appraisal and meta-analysis 
of published BV studies is possible through application 
of the Biological Variation Data Critical Appraisal Check-
list (BIVAC), published in 2017. The BIVAC compliant 
large-scale European Biological Variation Study delivers 
updated high-quality BV data for a wide range of meas-
urands. Other significant developments include the pub-
lication of a Medical Subject Heading term for BV and 
recommendations for common terminology for reporting 
of BV data. In the near future, global BV estimates derived 
from meta-analysis of BIVAC appraised publications will 
be accessible in a Biological Variation Database at the 
EFLM website. The availability of these high-quality data, 
which have many applications that impact on the qual-
ity and interpretation of clinical laboratory results, will 
afford improved patient care.
Keywords: analytical performance specification; biologi-
cal variation; evidence-based medicine; meta-analysis; 
reference change values.
Introduction
Many different sources of variation may impact upon labo-
ratory test results as an individual is monitored over time. 
Natural biological variation (BV) describes the variation 
in constituents regulated by homeostatic processes in the 
body [1]. Many measurands of clinical interest are charac-
terized by random variation around a stable homeostatic 
set-point (e.g. serum sodium concentration), whereas 
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others display change during the lifetime of an individual 
or predictable cyclical variation (e.g. pituitary gonado-
tropins in females). An understanding of this variation 
is required to enable appropriate application of clinical 
laboratory measurements. The magnitude of within-sub-
ject BV (CVI) describes the variation observed within an 
individual and the between-subject BV (CVG) the variation 
between individuals. BV data can be quantified to these 
ends; the resultant data enabling (1) setting analytical 
performance specifications (APS), (2) determination of 
reference change values (RCV) to assess the significance 
of change in serial measurements within a subject and 
(3) the derivation of index of individuality to assess the 
applicability of population based reference intervals [2]. 
The utility and validity of APS and other applications 
for diagnosis and monitoring based on BV data deliver 
a requirement that the applied BV data must be of high 
quality and relevant to the population served by the labo-
ratory. This raises an issue in that BV data are reference 
data, but they are often applied without this understand-
ing. This leads to indiscriminate application of the data 
to populations across health care systems that may have 
characteristics that are different to the reference popula-
tion. Thus, this delivers an imperative for those who use 
published BV data to apply the sort of scrutiny that they 
might apply when adopting population based reference 
intervals. Furthermore, BV estimates for the same meas-
urand obtained from independent studies may deliver 
estimates that vary substantially. The reason for this vari-
ation may be multi-factorial with lack of harmonization in 
study design, applied methodology and data handling for 
BV studies representing a major component source. There 
are a considerable number of published BV studies, with 
varying quality, stretching back over 40 years. Access to a 
compilation of these data has been enabled via an online 
database which presents BV data from studies identified 
through literature searches. The BV data are presented 
for a range of measurands alongside APS for bias, impre-
cision and total error derived from those data [3]. This 
is the work of the Analytical Quality Commission of the 
Spanish Society of Laboratory Medicine (SEQCML) [4], first 
presented at the Stockholm Conference in 1999 [5]. The 
database was updated every 2 years until 2014 [6] and has 
proven a useful source of BV data for the laboratory com-
munity. However, a number of questions have been raised 
regarding the accuracy of the estimates presented in this 
database [7, 8]. Prior to inclusion of the data into the pool 
from which the online 2014 BV database is compiled, pub-
lications on BV have been reviewed with regard to a set 
of criteria, such as the applied statistical model and ratio 
between analytical variation (CVA) and CVI estimates [6]. 
However, a rigorous appraisal with regard to study design 
or statistical analysis has not been performed. Further-
more, the validity of the methods used for generation of 
the global estimates of BV has been questioned and the 
estimates provided in the database have been unaccom-
panied by measures of uncertainty. That estimates from 
historical studies employing obsolete analytical methods 
may be included delivers a further degree of complexity 
to be considered by users. It is thus a concern that the 
headline BV estimates from this compiled database may 
not be fit for purpose and not the product of a harmonized 
approach to delivery. The data are applied by the laborato-
ries and clinicians in their everyday practice and this may 
both lead to adoption of inappropriate APS and also con-
sequences for patients’ diagnosis and monitoring.
Several initiatives have been established to provide 
a more harmonized practice and consequent delivery of 
fit for purpose and appropriately characterized BV esti-
mates; they include those driven by the European Fed-
eration of Clinical Chemistry and Laboratory Medicine 
(EFLM) Working Group on Biological Variation (WG-BV) 
[9] and the Task and Finish Group for the Biological Varia-
tion Database (TFG-BVD) [10]. This article aims to identify 
challenges in the generation and application of BV data 
and describes EFLM initiatives and other important har-
monization contributions that aim to provide solutions to 
the many challenges identified to assure the delivery of BV 
estimates that are fit for purpose to enable safe and effec-
tive clinical applications.
Generation and estimation 
of  components of BV
Study design and reliability
Numerous studies on BV components have been pub-
lished during the last four decades. There are variations 
between these publications in study design, methodol-
ogy and applied statistical approach that may affect the 
BV estimates they present. To generate high-quality BV 
data, adherence to strict experimental and statistical 
protocols is required. Furthermore, in order for estimates 
to be applicable in clinical practice today, the analytical 
methods used to derive the BV data must be comparable 
with contemporary methods in terms of analytical speci-
ficity, as obsolete methods using different principles may 
in fact deliver different BV estimates (e.g. switching from 
competitive immunoassay to immunometric assays for 
parathyroid hormone). Typically, when generating BV 
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data, a group of reference individuals, in most cases cited 
as apparently healthy individuals, are studied. From each 
of these individuals, specimens are drawn at regular and 
appropriate time intervals while minimizing all sources 
of pre-analytical variation. All specimens must be drawn, 
processed, transported and stored under controlled and 
standardized conditions [2]. Ideally, analysis should be 
performed in duplicate, with all samples from the same 
individual being processed in the same analytical run if 
possible, while minimizing analytical sources of varia-
tion. Thereafter, appropriate statistical analysis includ-
ing assessment of outliers and homogeneity of variances 
must be applied, followed by dissection of the CVA, CVI, 
and CVG components by a nested analysis of variance 
(ANOVA), general/generalized linear model or a similar 
approach [2].
To produce robust, well-characterized BV data and 
to ensure that data are transferable across health care 
systems and different populations, BV studies must 
conform to an ideal standardized approach, be ade-
quately powered and properly documented at the report-
ing stage. This is, unfortunately, not always the case. The 
number of replicates, number of samples and number of 
individuals included in the study influence the reliability 
and confidence intervals (CI) of the BV estimates, and the 
effect of these variables varies with the ratio of analytical 
standard deviation (SDA) to within-subject SD (SDI) [11]. 
Generally, the lower the SDA/SDI ratio, the narrower the 
CIs. If subgroups are to be explored, a balanced number of 
subjects in each planned sub-group is preferable. When 
published, BV estimates must be accompanied by their 
corresponding CIs to allow for the assessment of their reli-
ability, comparison between subgroups and the compara-
bility with other studies.
The European Biological Variation Study 
(EuBIVAS)
Responding to the need for reliable BV estimates deliv-
ered from big high-quality studies, the EFLM WG-BV 
has designed and implemented the European Biologi-
cal Variation Study (EuBIVAS) [12]. In the EuBIVAS, six 
European clinical laboratories in five different countries 
followed a strict, detailed protocol for the recruitment of 
subjects and for the pre-analytical phase [13]. The study 
population included 91 healthy volunteers (38 males and 
53 females, age 21–69 years). Fasting blood samples were 
drawn for 10 consecutive weeks (April–June 2015) for all 
individuals. All samples were processed and prepared in 
the same way as detailed [13] and stored at –80 °C prior to 
shipment on dry-ice to the coordinating center in Milan. 
All samples from each of the participants were analyzed in 
duplicate on platforms within the Milan laboratory under 
standardized conditions. The resultant data sets under-
went rigorous scrutiny and appropriate statistical analy-
sis to enable delivery of BV estimates accompanied by 
CIs. So far, estimates for liver enzymes [14] and creatinine 
using enzymatic and alkaline picrate methods [15] have 
been published. For these measurands, EuBIVAS esti-
mates are lower than the corresponding estimates avail-
able in the online 2014 BV database (Table 1) [3]. Though 
the reasons for this may be multi-factorial, our data so far 
indicate that a large and strictly performed study such as 
the EuBIVAS delivers lower estimates than many other BV 
studies; these differences have implications for the setting 
of APS, diagnosis and monitoring and other applications 
of BV data. In addition, the EuBIVAS study has enabled 
comparison of measurements using different analytical 
approaches; in the case of serum creatinine the EuBIVAS 
results indicated that current alkaline picrate methods 
may not meet BV-based APS for imprecision [15]. The next 
phase of the EuBIVAS, providing BV estimates for electro-
lytes, lipids, hormones and specific proteins, is under way 
[12]. Thus, the EuBIVAS provides a valuable resource and 
infra-structure to enable delivery of high-quality and well 
characterized, and therefore transportable, BV data for a 
large number of measurands, using a protocol that is fully 
compliant with the newly developed Biological Variation 
Data Critical Appraisal Checklist (BIVAC) [16].
Critical appraisal of BV publications 
and the delivery of global estimates
Following the 1st Strategic Conference of the EFLM defin-
ing APS in November 2014 [17], the EFLM TFG-BVD was 
established [10], with the objective to appraise the quality 
of BV data that is publicly available. Its terms of reference 
were to develop a critical appraisal list for the evaluation 
of BV studies, to use this to assess the existing literature on 
BV and to extract essential information from those papers 
and to summarize the results. The remit has expanded to 
the development of a new database containing measures 
of BV with indications of their quality and associated APS. 
The TFG-BVD was made up by members from the EFLM 
WG-BV [9], the Analytical Quality Commission of the 
SEQCML [4], and other key persons with experience in the-
oretical and practical aspects of generating BV data. The 
results of the work of this TFG are three-fold. Firstly, the 
TFG-BVD in collaboration with the WG-BV has developed 
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the recently published BIVAC [16]. Secondly, as part of this 
work, a meta-analysis approach for pooling BIVAC com-
pliant estimates to provide global BV estimate has been 
developed. And thirdly, using the results of this work, the 
TFG, now transformed to a more permanent Task Group, 
is in the process of establishing a new Biological Variation 
Database, to be available at the EFLM website.
The Biological Variation Data Critical 
Appraisal Checklist (BIVAC)
The BIVAC is designed to assess the quality of BV publi-
cations by verifying whether all essential elements that 
may impact upon veracity and utility of the associated BV 
estimates are present [16]. Its main focuses are the effect 
of study design, the measurement procedure and statisti-
cal handling of data on CVI estimates. The BIVAC consists 
of 14 quality items (QI), which can be awarded scores A, 
B, C or D (Table 2) [16]. Based on the individual scores for 
each of the QI, an overall grade is set for the publication 
under review. The grade A is achieved if the publication 
shows full compliance with all BIVAC QI. If the lowest 
score for any QI is a B, then the overall grade is a B and 
similarly C or D if the lowest QI score is a C or D, respec-
tively. In the BIVAC scoring system, the QI related to the 
overall grade are shown as a subscript, as exemplified 
by C4,8,13 and B6,7,8,9,11,13. BV estimates derived from studies 
that receive one or more D scores are considered unsuit-
able for use in clinical practice. The BIVAC QI relating to 
Table 1: Biological variation within-subject (CVI) and between-subject (CVG) estimates from the European Biological Variation Study 
(EuBIVAS) with 95% confidence intervals (CI) for serum creatinine concentrations and enzyme activities and corresponding estimates avail-
able in the online 2014 BV database.
Measurand   Study 
population
 
 
EuBIVASa 
 
Online 2014 BV 
database
CVI % (95% CI)  CVG % (95% CI) CVI, %  CVG, %
Creatinine (enzymatic method)   All subjects   4.4 (4.2–4.7)  14.8 (12.8–17.8)  6.0  14.7
  Males   4.2 (4.0–4.7)  12.8 (10.1–17.0)   
  Females   4.6 (4.3–4.9)  10.2 (8.4–13.0)   
Alanine amino transferase (ALT)   All subjects   9.3 (8.7–10.0)  28.0 (24.7–33.9)  19.4  41.6
  Males   10.1 (9.2–11.2)  28.2 (22.6–37.4)   
  Females   9.6 (8.8–10.5)  25.2 (21.3–32.1)   
Aspartate aminotransferase (AST)   All subjects   9.5 (9.0–10.2)  20.3 (17.7–24.2)  12.3  23.1
  Males   10.3 (9.5–11.3)  14.7 (12.4–20.3)   
  Females   8.9 (8.3–9.8)  22.4 (18.7–28.3)   
Gamma-glutamyl transferase (GGT)  All subjects   8.9 (8.1–9.7)  45.1 (38.9–54.2)  13.4  42.2
  Males   8.3 (7.1–9.5)  41.7 (33.5–57.4)   
  Females   8.3 (7.4–9.5)  34.2 (28.1–43.4)   
Alkaline phosphatase (ALP)   All subjects   5.3 (5.0–5.7)  24.9 (21.4–29.3)  6.5  26.1
  Males   5.0 (4.6–5.5)  25.4 (20.3–34.1)   
  Females   5.4 (5.1–5.9)  24.2 (20.6–30.9)   
Lactate dehydrogenase (LDH)   All subjects   5.2 (5.0–5.5)  12.6 (10.8–14.7)  8.6  14.7
  Males   5.5 (5.1–6.0)  10.2 (8.1–13.3)   
  Females   5.2 (4.9–5.6)  14.0 (11.6–17.3)   
Creatine kinase (CK)   All subjects   14.5 (13.8–15.4)  37.9 (32.8–45.8)  22.8  40
  Males   16.0 (14.8–17.5)  31.5 (25.2–42.5)   
  Females   15.7 (14.6–16.8)  30.5 (24.8–38.4)   
Amylase   All subjects   6.8 (6.5–7.2)  30.4 (26.5–36.3)  8.7  28.3
  Males   6.3 (5.9–6.9)  30.0 (23.7–39.1)   
  Females   7.1 (6.7–7.6)  31.4 (26.6–40.0)   
Pancreatic amylase   All subjects   6.3 (6.0–6.7)  24.9 (21.9–30.1)  11.7  29.9
  Males   5.9 (5.5–6.5)  23.3 (18.8–30.8)   
  Females   6.8 (6.3–7.3)  26.0 (22.3–34.2)   
Lipase   All subjects   7.7 (7.2–8.3)  23.8 (20.6–28.2)  32.2  31.8
  Males   6.4 (5.5–7.2)  22.2 (18.1–29.2)   
  Females   8.9 (8.3–9.8)  23.9 (19.9–30.2)   
aEuBIVAS estimates adapted from Carobene et al. [14, 15].
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subjects (QI 2), samples (QI 3) and the measurement pro-
cedure (QI 4) are considered critical for the reliability and 
applicability of the associated measures of BV and thus 
can be scored as D (Table 2). It is an absolute requirement 
that populations from which BV data have been derived 
are adequately characterized. Furthermore, details on the 
study population, samples, sample material and timing 
of samples are necessary to compare with other studies, 
to deliver CIs and to generate global BV estimates. Addi-
tionally, it is essential that historical publications assess 
the same measurand as contemporary methods for the 
reported BV estimates to be relevant. QI 5–7 refer to pre-
analytical procedures, estimates of CVA and demonstra-
tion of steady state, all of which are required to obtain 
high-quality BV estimates. Statistical elements QI 8–12 
relate to analysis of outliers, normality, homogeneity of 
variances, the applied statistical model and CI which are 
central for the quality of the associated BV estimates and 
their applicability. QI 1 (scale), 13 (number of included 
results) and 14 (concentrations) do not reflect the reliabil-
ity of the BV estimates in themselves, but are necessary 
elements for interpretation and application of the data. 
Applying the BIVAC to 128 BV publications for 28 differ-
ent measurands revealed that the QI for outlier analy-
sis and variance homogeneity testing were most often 
scored as C, meaning that appropriate analysis of these 
elements were missing in more than 60% of publications 
[16]. Although many of the historical papers on BV were 
performed according to the standards existing at the time 
of publication, it is, based on our review, evident that 
many BV publications omit, or fail to address, essential 
elements, in particular for statistical analysis, which may 
affect the reliability and applicability of the reported BV 
estimates.
Meta-analysis of BV studies
For commonly requested measurands, many studies on 
BV have been published, as exemplified for total choles-
terol, where 46 publications are included in the online 
2014 BV database [3]. The common estimate that is pre-
sented in this database represents the median of esti-
mates from studies fulfilling its inclusion criteria [6]. We 
have recently developed a meta-analysis approach for the 
delivery of global estimates [16]. With this approach, BV 
publications for the measurand in question are identi-
fied by systematic searches and relevant publications are 
thereafter appraised by the BIVAC. Only studies receiving 
an overall BIVAC grade A, B or C are considered fit to be 
considered for the meta-analysis. Thereafter, the study 
design is reviewed so that only studies with similar char-
acteristics are included in the meta-analysis; as a first step 
studies performed in healthy adults where sampling is 
weekly. For the meta-analysis, the associated BIVAC grade 
and the width of the CI are used as weight, with the global 
estimate being delivered by a weighted median approach 
[16]. If a sufficient number of higher quality studies, i.e. 
BIVAC grades A and B, are available, the global estimate 
may be based on these alone.
The EFLM Biological Variation Database
As part of our initial BIVAC review of BV publications for 
enzymes, lipids, kidney and diabetes related measur-
ands [16], work is in progress in providing updated global 
estimates for all these 28 measurands. These, and other 
measurands that will be critically appraised in the near 
future, will be published in a new Biological Variation 
Database, available on the EFLM website. Here global 
BV estimates with the evidence behind them and related 
APS will be accessible, with separate estimates being 
delivered for different populations and sampling inter-
vals when relevant. This will be an important initiative 
in providing updated evidence-based global estimates 
easily accessible to users. Once this database covers the 
majority of relevant measurands and gains momentum 
in reaching potential users, it may contribute to a har-
monized approach so that where appropriate, the same 
global BV estimates and APS will be applied in laborato-
ries worldwide.
Table 2: The quality items of the Biological Variation Data Critical 
Appraisal Checklist with achievable scores.a
Quality item 
number
  Quality item   Achievable 
scores
1   Scale   A   B   –  –
2   Subjects   A   B   C   D
3   Samples   A   B   C   D
4   Measurand   A   B   C   D
5   Pre-analytical procedures   A   B   C   –
6   Estimates of analytical variation  A   B   C   –
7   Steady state   A   B   C   –
8   Outliers   A   B   C   –
9   Normally distributed data   A   B   –  –
10   Variance homogeneity   A   –  C   –
11   Statistical method   A   B   C   –
12   Confidence limits   A   –  C   –
13   Number of included results   A   B   C   –
14   Concentrations   A   B   –  –
aAdapted from Aarsand et al. [16].
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Reporting of BV data and BV 
terminology
The Biological Variation Data Reporting 
Checklist
There have historically been no internationally recognized 
standards for production, reporting and transmission of 
BV data. The WG-BV published in 2015 the Biological 
Variation Data Reporting Checklist [18], which identifies 
key elements required in studies to enable accurate and 
effective use of BV data across population groups and 
healthcare systems. It is based on the same structure as 
the STARD [19] and identifies six main minimum data set 
domains including (1) title/abstract/keywords, (2) intro-
duction, (3) methods, (4) data analysis, (5) results and (6) 
discussion. Compliance with this checklist indicates that 
studies are fit for purpose, that essential statistical analy-
ses such as outlier and variance homogeneity testing have 
been reported, that common terminology has been used 
and that BV estimates are accompanied by key metadata. 
Additionally, the BIVAC, although designed for critical 
appraisal of already published studies (16), provides a 
detailed guide for those designing and delivering future 
studies and an aide for reviewers of manuscripts reporting 
on those to assure publication of the required high-quality 
BV publications.
Terminology for components of BV
There is a wide range of terms and symbols used for 
the definition of components of BV in the published lit-
erature. A recent study reviewed the 13  highest ranked 
clinical chemistry journals and identified 68 terms and 
25 symbols for components related to individuals and 47 
terms and 18  symbols for components related to groups 
of individuals [20]. There is a clear need for a harmonized 
use of terminology, and the EFLM WG-BV supports the 
terms and symbols for components of BV suggested by 
Simundic et al. [20], as outlined in Table 3. This terminol-
ogy has also been supported by the Clinical Chemistry 
and Laboratory Medicine [21]. Additionally, up until now, 
there has not been a Medical Subject Heading (MeSH) 
heading for BV, which both adds to the varied use of BV 
terms as well as complicating literature-searching strat-
egies [16]. The WG-BV suggested in 2016 the establish-
ment of a new MeSH term for “Biological Variation” to 
the National Library of Medicine. This was accepted and 
the MeSH term has been available from December 2017, 
thus facilitating systematic searches for BV publications. 
However, the National Library of Medicine usually does 
not re-index previously indexed articles when new head-
ings are added.
Applications of BV data
There are many applications for BV data in the laboratory 
and in clinical practice, most central are the setting of 
APS and RCV. It has recently been suggested that labora-
tory tests can be allocated to three different models for the 
determination of APS; (1) the effect on the clinical outcome, 
(2) BV data or, (3) the state-of-the-art of measurement [22]. 
It has been suggested that most measurands should have 
APS assigned using the BV model [22, 23], further empha-
sizing the central role of BV data in laboratory medicine. 
Additionally, for many measurands where the outcome 
model is recommended, studies are not currently available 
to support this approach. In such cases application of the 
BV model may represent a pragmatic interim approach to 
setting of APS if appropriate data are available. For RCV, 
they are at any given level of probability a function of 
the CVA and CVI. For local use, local RCV must be calcu-
lated based on appropriate CVA from the laboratory’s own 
quality control for the relevant time interval and the rele-
vant z-value chosen, depending on the clinical question in 
mind and the wanted level of probability [2]. A log-normal 
approach as described below is preferable for calculating 
RCV when using estimates of CVA and CVI in % [24], result-
ing in asymmetric limits, i.e. differently sized RCV for a 
decrease and an increase in the measurand concentration:
2 2
A,log e ASD lo (g CV 1)= +
2 2
I,log e ISD lo (g CV 1)= +
2 2
combined,log A,log I,logSD SD SD= +
combined ,log(( Z 2 SD ) 1)RCV% 100% .e α± × × −= ×
Table 3: Terminology and abbreviations for biological variation 
related components and applications.
Abbreviation/symbol Term
CVI Within-subject biological variation
CVG Between-subject biological variation
CVA Analytical variation
RCV Reference change value
II Index of individuality
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This approach is also superior to classical RCV cal-
culation in that it is not possible to achieve paradoxical 
decreases greater than 100% [24]. For the best performance, 
this approach assumes log-normal distributed data or esti-
mates of CVI <12% [25, 26]. A rearrangement of the RCV 
equation can make z the unknown so that, for any change 
in serial results detected, using the estimates of CVI and 
CVA, the probability that the seen change is significant can 
be calculated [2]. Additionally, a model has been devel-
oped to set limits for significant bidirectional changes 
when more than two serial results are available [27].
Conclusions
Over time, concern has been raised regarding the quality 
of available BV estimates and the effect of their applica-
tion in clinical practice. With this in mind, a number of 
initiatives have been launched aiming to deliver robust 
and reliable BV estimates. Harmonized approaches to the 
future delivery and application of these important data 
will drive up their quality and assure safe use. An under-
standing of the importance of study design and power to 
deliver robust data with narrow CI has been published. 
The need to derive new BV estimates for existing and new 
analytical systems has led to the implementation of the 
EuBIVAS. This is a large-scale, highly powered and BIVAC 
compliant BV study providing updated and well-charac-
terized BV estimates for many clinically important meas-
urands. EFLM groups have developed both the BIVAC for 
critical appraisal of existing BV studies and an approach 
to meta-analysis for BV studies that enables more robust 
point estimates of BV from multiple quality assessed 
studies. The establishment of a MeSH term, common ter-
minology and a standard for reporting of BV studies will 
provide accessibility and understanding of and trans-
portability of the published BV data. The results of these 
initiatives will enable delivery of a new EFLM Biological 
Variation Database, where global BV estimates resulting 
from meta-analysis of critically appraised publications 
will be made publicly available. The use of this evidence-
based database will provide laboratories the opportunity 
to implement global, quality assured BV estimates and 
APS and thus contribute to a harmonized use of these data 
and potentially better quality of patient care.
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